Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study - Takeaways - MDSpire

Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study

  • By

  • Shungo Yamamoto

  • Akihiro Shiroshita

  • Yuki Kataoka

  • Hidehiro Someko

  • March 5, 2025

  • 0 min

Share

  • 1

    Ampicillin-sulbactam was associated with higher in-hospital mortality compared to ceftriaxone in elderly patients with community-acquired pneumonia.

  • 2

    The study analyzed data from 26,633 older patients hospitalized for community-acquired pneumonia between May 2010 and June 2023.

  • 3

    The incidence of Clostridioides difficile infection was numerically higher in the ampicillin-sulbactam group than in the ceftriaxone group.

  • 4

    This research utilized a target trial emulation framework to compare the effectiveness of the two antibiotic treatments.

  • 5

    Current guidelines do not mandate routine anaerobic coverage for community-acquired pneumonia, reflecting changes in bacterial prevalence.

Original Source(s)

Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study

  • by Shungo Yamamoto, Akihiro Shiroshita, Yuki Kataoka, Hidehiro Someko

  • March 5, 2025

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Clostridium difficile infection after stoma reversal surgery: a systematic review and meta-analysis of the literature

Reply to Olle et al.